Indegene, Datavant partner to enhance clinical trial recruitment

20 Sep 2025 Evaluate

Indegene and Datavant, the data collaboration platform trusted for healthcare, have entered into strategic partnership to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies. By embedding Datavant’s bespoke data enrichment capabilities into Indegene’s NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures, and more efficient recruitment processes for biopharmaceutical organizations. 

Datavant operates the nation’s largest health data retrieval network, spanning more than 80,000 hospitals and clinics and processing over 100 million patient records annually. Combined with Indegene’s suite of digitally powered solutions for clinical trial recruitment, the partnership streamlines the identification of suitable participants for studies based on specific health data criteria. The partnership enables biopharma companies to reduce site-level screen failures, accelerate enrollment timelines, improve the screen-to-randomization ratios, and drive more informed decision-making.

Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.

Indegene Share Price

533.20 -1.05 (-0.20%)
08-Dec-2025 11:24 View Price Chart
Peers
Company Name CMP
Syngene Internation. 635.00
Indegene 533.20
CMS Info Systems 349.10
Sagility 48.41
Smartworks Coworking 440.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×